千亿·国际(中国)唯一官方网站
Other Affiliated Sites
Simplified Chinese
Traditional Chinese
About Hepalink
Group Profile
Corporate Philosophy
Milestones
Leadership Team
Scientific Advisory Board
Our Businesses
Heparin Business
Global Industrial Chain
Global Heparin Injections Business
Product Profile
CDMO Services
Innovative Drugs
Global Manufacturing
Company News
Investor Relations
Corporate Governance
Disclosures
Stock Information
IR Events
IR Contact
Join Us
Career Development
Contact Us
Create Value for Investors Through
Safe and Stable Operations
Corporate Governance
Disclosures
Stock Information
IR Events
IR Contact
Disclosures
A-Share Information
H-Share Information
A-Share Information
H-Share Information
2023.11.23
NOTIFICATION LETTER
2023.11.23
(1) PROPOSED AMENDMENTS TO THE ARTICLES AND RELATED RULES OF PROCEDURES OF THE C...
2023.11.21
PROPOSED AMENDMENTS TO THE ARTICLES AND PROPOSED CHANGE IN USE OF PROCEEDS
2023.11.21
千亿国际:第六届董事会第五次会议决议公告
2023.11.21
千亿国际:第六届监事会第四次会议决议公告
2023.11.21
千亿国际:关于变更H股募集资金使用用途的公告
2023.11.21
千亿国际:关于修订公司治理相关制度的公告
2023.11.21
千亿国际:关于召开2023年第一次临时股东大会、2023年第一次A股类别股东会议及第一次H股类...
2023.10.30
2023 THIRD QUARTERLY REPORT
2023.10.30
千亿国际:2023年三季度报告
第一页
上一页
13
14
15
16
17
下一页
最后一页
About Hepalink
Group Profile
Corporate Philosophy
Milestones
Leadership Team
Scientific Advisory Board
Our Businesses
Heparin Business
CDMO Services
Innovative Drugs
Global Manufacturing
Company News
Investor Relations
Corporate Governance
Disclosures
Stock Information
IR Events
IR Contact
Join Us
Career Development
Contact Us
Official WeChat Account
Legal Statement
·
Environmental Disclosure
Copyright © 2024 Hepalink Group. All Rights Reserved.